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ABSTRACT
Objective: The main objective of the study was to assess the quality attribute of generic brands and newly formulated tablet of glimepiride and 
compare their drug release profile with innovator brand.
Methods: Different brands were purchased from different markets of UAE. The validated high-performance liquid chromatography method was used 
to assess the quantitative analysis of glimepiride. The linearity of curve (r² = 0.9999) indicated the accuracy and precision of the analytical method. 
Comparative dissolution of newly formulated and generic tablets was carried out using USP dissolution apparatus II. Study was accomplished in 
phosphate buffer (pH = 7.8), the paddle speed was adjusted at 75 rpm. F1 and F2 factor among the brands and kinetic assessment were done to obtain 
the order of release.
Results: Dissolution profiles of formulated tablets were almost same as that of innovator, 91.53 and 94.9, respectively, in 15 min. The statistical 
value between the different brands (F = 3.698) indicated that there were some differences among the few groups of tablets and p-value (0.002154) 
indicated that it supported H1 hypothesis. First-order and Weibull models described the drug release with r2 value of 0.9981–0.927210 and 0.9992–
0.9835, respectively. Stability of optimized formulated batch was also examined.
Conclusion: It was concluded that the formulated tablets are stable and pharmaceutically as good as the innovators; however, all the selected brands 
could not be used interchangeably in the clinical practice. It was also concluded that the scrutiny and screening of the drug products, available in the 
markets, can help to build a better health-care setup.
Keywords: Comparative dissolution behavior, Glimepiride, High-performance liquid chromatography method of analysis, Pharmaceutical quality 
assessment, Stability study of tablets.
INTRODUCTION
Glimepiride is useful in the treatment of non-insulin dependent diabetes 
mellitus [1,2]. It is 1-(p-(2-(3-ethyle-4-methyl-2-oxo-3- pyrroline-1-
carboxamido) ethyl) phenyl) sulfonyl)-3-(trans-4-methylcyclohexyl) 
urea which belongs to third generation of hypoglycemic sulfonylurea. 
The use of oral antidiabetic drugs is more preferred as compared to 
other routes for the treatment of disease. The basic objective of these 
drugs is to control the glycemic condition of patients by controlling and 
avoiding hypoglycemia and weight gain that helps to decrease the risk 
of potential micro- and macro-vascular impediments [3].
Glimepiride falls in BCS Class II, it has low solubility and high 
permeability making it difficult to manufacture tablets with good 
dissolution rate that consequently affects the systemic availability of 
drug in the body. In 2007, Adegbolagun et al. [4] suggested a need to 
analyze and evaluate the generic brands available in the market. These 
drugs should be analyzed for their chemical and biopharmaceutical 
equivalence, strength, quality, purity, and releasing profile of active 
ingredient in comparison of innovator drug.
The aim of the present study was to assess the characteristics of 
different brands and newly formulated immediate release tablets [5] 
and compares their dissolution profile with innovator brands. The 
focus of the study was to verify and optimize the new formulation as 
well as to evaluate the quality of generic brands available in different 
market of UAE (Ras Al Khaimah, Dubai, and Abu Dhabi). These brands of 
glimepiride were manufactured by different pharmaceutical companies, 
including UAE, Saudi Arabia, Pakistan, Jordan, and India. The study was 
also concentrated on the suitability of the newly formulated tablets 
which was estimated by accelerated stability studies. Consequently, 
the study was performed to provide the guideline to the physicians 
and pharmacists on the basis of which they can select the appropriate 
brands for their patients.
METHODS
Glimepiride reference powder (purity 99.61%) was obtained as a 
gift sample from Julphar, Ras Al Khaimah, UAE. Brands of glimepiride 
tablets purchased from UAE (Ras Al Khaimah, Dubai, and Abu Dhabi), 
Lactose monohydrate (VWR International, Germany), Microcrystalline 
cellulose (Fluka–Biochemika, Germany), Polyvinyl Pyrrolidone K-30 
(PanReac–AppliChem, Italy), Sodium Starch Glycolate (Gift sample from 
Julphar), Mg stearate (Sigma Aldrich, Germany), and all other chemicals 
and solvents such as methanol, acetonitrile, and phosphate buffer used 
were of analytical reagent grade.
Method of analysis
To achieve the consistent, reliable, and accurate data for the analysis of 
drug in dosage form, reported high-performance liquid chromatography 
(HPLC) [6] analytical method was first validated as per ICH guideline [7] 
and was then used to estimate glimepiride in marketed as well as in 
newly formulated tablets [5].
Mobile phase preparation
Accurately, weighed 0.5 g of monobasic sodium phosphate was taken 
and dissolved in 500 ml of double distill water. It was thoroughly 
mixed and the pH was adjusted at 2.4 with 10% orthophosphoric acid. 
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Acetonitrile with phosphate buffer in the ratio of 1:1 was added, mixed, 
and filtered through 0.45 µm Millipore filter paper.
Calibration curve and estimation of glimepiride
A series of dilutions was prepared in the diluent mixture (ACN: H2O; 
9:1) according to the study design [5]. The concentrations of these 
solutions were 2.5, 5, 7.5, 10, and 12.5 µg/ml, respectively. Absorbance 
of the solutions was measured at λ = 228 nm.
Experimental Design
In vitro pharmaceutical quality of different brands of glimepiride 
tablets was estimated to establish the in vitro bioequivalence among 
the different generic brands. The preliminary information of different 
brands was used to construct the basic design and formula for new 
tablets [5] and then to compare this newly formulated tablets with 
different brands to verify and confirm the in vitro equivalency of it.
Optimized formula for new tablets
Using the basic idea of formulation from innovator tablet (Glim-A; 
2 mg), new tablets of glimepiride were prepared by Slurry method [5]. 
Total ten formulations were designed using different composition of 
polyvinyl pyrrolidone K-30, Crospovidone, tween 80, and sodium starch 
glycolate. The following composition was selected as finally optimized 
Batch/check point batch (G10) with dissolution rate of more than 90% 
in 15 min (Table 1).
Pharmaceutical evaluation of marketed and newly formulated 
tablets
Different brands of glimepiride are available in the market of UAE. Out 
of them, eight brands were selected and evaluated for weight variation, 
hardness, disintegration, wetting time, and content assay. The release 
profile of drug from their tablets was estimated and compared by 
different statistics.
Drug release kinetics studies
The dissolution tests were carried out using the Type-II apparatus 
(paddle), at 75 rpm. Dissolution was done in phosphate buffer (pH 7.8) 
with multipoint sampling at different time intervals of 5, 10, 15, 20, 30, 
and 45 min and analyzed by HPLC method at λmax = 228 nm.
The dissolution data of prototype tablets (G10) were analyzed with 
various kinetic equations in comparison to generic (Glim-B - H) and 
Innovator tablets (Glim-A), to understand the kinetic release and ability 
of the tablets [8,9].
Stability studies
One of the most important pharmaceutical parameters to assess the 
quality of any newly designed formulation is the stability of the drug 
in its dosage form. After the quality assessment of tablets, G10 was 
kept for stability for 3 months (0, 1, 2, and 3 months) under accelerated 
conditions, 40±2°C; 75±5% R.H, as per the ICH guidelines [10].
RESULTS AND DISCUSSION
Glimepiride is used to reduce both fasting and postprandial blood 
glucose. These reductions are dose dependent over a range of 
1–8 mg daily [11]. On the other hand, it is a poorly soluble drug 
that makes it difficult to maintain the consistency of quality and 
performance. The performance of solid tablets depends on the 
release of the drug from their dosage form. In vitro dissolution 
or drug release is supposed to work as a powerful tool in the 
measurement of quality attributes of new formulation as well as for 
the assessment of generic products.
In 2018, Ministry of Health and Prevention issued a circular on 
withdrawal of diabetic medicine from the UAE market [12]. Under these 
situations, time to time review of post marketed generic drug products 
is expected to not only improve the overall health delivery systems [4] 
but also to reduce the cost of treatment, especially for the low-income 
developing countries [13]. Moreover, the distribution of these generic 
brands may be associated with many problems due to fake, counterfeit, 
and substandard quality of drug products that are main triggers for 
morbidity and mortality [14, 15].
In 2011, the International Diabetes Federation (IDF) estimated 366.2 
million adult populations with diabetes, which is estimated to grow 
by 51%–551.8 million by 2030 [16]. Glimepiride is widely used as 
monotherapy or in combination with insulin for diabetes mellitus 
type II [17]. However, UK Prospective Diabetes Study (UKPDS), 
American Diabetes Association (ADA), and UK National Institute for 
Health and Clinical Excellence (NICE) incorporated the findings of some 
research that sulfonylureas can increase risks of hypoglycemia, weight 
gain, and cardiovascular issues [18, 19].
Different studies revealed that the generic products with the 
same amount and salt of active ingredient display differences in 
their therapeutic responses. Lot of generic products that are not 
interchangeable with their reference or some time even with each 
other, have been reported [16, 17, 20, 21] that makes it important to 
conduct the post-market evaluation of products to reduce the chances 
of error in the selection of good one for the patients.
For the accurate and precise analysis, it is important to validate the 
analytical method as per the availability and feasibility of the equipment 
before starting the estimation [5]. Calibration curve for glimepiride 
was constructed in the concentration range of 2.5–12.5 µg/ml and was 
found to be linear with the regression analysis (R2) of 0.9999 (Fig. 1).
The series of tests defined by the pharmacopeias were conducted on 
different brands to evaluate their pharmaceutical characteristics and 
were compared with innovator to check and verify the quality attributes 
of tablets.
The weight variation of different tablets was calculated with their 
standard deviation, that is, between 141.15±1.80 and 200.95±1.61, 
whereas the newly formulated tablets showed more consistency in 
their weight with less SD 170.45±1.04. In 1993, Gupta [22] investigated 
that hardness depends on the nature and quantity of excipients. The 
results of study showed that the proportion of selected excipients for 
Table 1: Optimized formula for new tablets (G10)





Polyvinyl Pyrrolidone K-30 1
Tween 80 2
Sodium Starch Glycolate 8
Mg stearate 1
Total weight 170 Fig. 1: Calibration curve (linearity)
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new tablets (G10) was appropriate as the hardness was 4.35±0.104 
which was more than innovator tablets (Table 2).
The results of disintegration test presented that Glim-D was disintegrated 
in 236.5±0.88 sec (3 min and 57.5 s), which was the highest time and 
Glim-B was within 3.0±0.07 s. Disintegration time of G10 is 96.8±1.22  s 
(1 min and 36.8 s) which is extremely near to that of innovator, that is, 
77.50±0.11 s (1 min and 17.5 s). In case of glimepiride, dissolution rate 
is considered as the rate limiting step for the drug absorption. In the 
illustration of formulated tablets [5], the targeted time for disintegration 
was kept <5 min (300 s), the concept was to facilitate faster disintegration 
to improve overall dissolution and solubility of drug (Table 2).
All the eight brands have no statistically significant difference in 
drug content (97.9–104.3%). The percentage content of G10 was 
100.34±0.66 that indicated the uniformity of powder blend. Wetting 
time was performed with three units of each marketed brand and the 
results were in the range of 4.80±1.73–118.00±3.15 s whereas G10 
has 94.00±1.55 s showing a good relationship with disintegration time 
(Table 2). Robustness and strength of tablets were checked by friability 
test. Veego Friability Apparatus was used to test the friability according 
to the USP and NF as shown in Table 2. The friability of G10 was found 
0.11±0.014, which indicated the durability and potential of tablets 
required for their transit.
In vitro drug release
Ninety percent of drugs are administered through oral route, so if the 
dissolution of the drug is slow, it leads to subsequently incomplete 
absorption and low bioavailability. The dissolution rate was estimated by 
validated HPLC method. This analysis was carried out to estimate whether 
the generic brands and newly formulated tablets had capability to release 
the drug as that of their innovator. G10, Glim-A, B, C, E, and F showed more 
than 85% in 15-min, Glim-G and Glim-H showed more than 85% in 30 min 
whereas the Glim-D released <85% even after 45 min (Fig. 2).
To confirm the releasing pattern of drug from these brands, ANOVA 
was also applied to estimate the variation among the brands [23]. The 
statistical value (F=3.698) indicated that it is not in the p<0.05 critical 
value accepted range: (−∞: 2.1521), so there were some differences 
among the few groups of tablets (Table 3). P-value is also smaller 
(0.002154) which indicates that it supports H1 hypothesis (Fig. 3).
In addition, the similarity and difference factor (F1 and F2) among 
the brands was also evaluated using Glim-A (innovator) as reference 
standard [24]. The results indicated that Glim-D did not comply with the 
F1 factor having 32.66% of difference. Whereas, three brands (Glim-C = 
48.62; Glim-D = 26.98, and Glim-H = 44.08) did not comply with the F2 
factor (Table 4). At the same time, newly formulated tablets were also 
compared with innovator to estimate the f1 and f2 factors which were 
7.02 and 56.77, respectively.
The dissolution data were also analyzed with various kinetic equations 
in comparison to Innovator (Glim-A). These kinetic models were 
estimated using DD solver (version 1.0). The Table 5 shows that the 
batches of formulations failed to obey the zero-order and Higuchi 
kinetics. Whereas, first-order and Weibull models describe the drug 
release with R2 value of G10 = 0.9905 and 0.9991, which is very similar to 
Glim-A for both model, that is, 0.9396 and 0.9992. The generics brands 
also obey the first-order kinetics and Weibull models with R2 = 0.9981–
0.9272 and 0.9975–0.9835, respectively. The first-order model helps 
to describe the relationship between pharmaceutical dosage form and 
the release pattern of drug from it. Glim-C, D, G, and H along with G10 
showed good commitment with Hixson-Crowell Model as compared 
to the Glim-A, B, E, and F that confirmed the size distribution study 
indicated most of the particle fell in the same size range.
Table 2: Pharmaceutical evaluations of G10 and marketed tablets












Glim-A (Innovator) 170.2±1.43 3.98±0.106 0.20±0.002 90.00±0.92 77.50±0.11 102.3±0.75
G10 (Formulated) 170.45±1.04 4.35±0.104 0.11±0.014 94.00±1.55 96.8±1.22 100.34±0.66
Glim-B 141.15±1.80 3.95±0.097 0.21±0.01 4.80±1.73 3.00±0.07 102.01±0.11
Glim-C 170.5±1.85 4.3±0.100 0.12±0.003 72.00±2.23 93.75±0.78 99.93±0.45
Glim-D 169.5±1.83 2.73±0.110 0.26±0.023 64.00±3.11 236.5±0.88 98.76±0.32
Glim-E 169.75±1.80 4.38±0.097 0.14±0.006 118.00±3.15 88.75±0.75 100.9±1.10
Glim-F 168.65±1.98 4.05±0.092 0.17±0.012 30.00±1.66 44.50±0.63 104.3±0.99
Glim-G 141.35±1.95 3.43±0.080 0.18±0.004 45.00±3.43 44.00±0.33 100.3±1.33
Glim-H 200.95±1.61 4.08±0.100 0.30±0.014 78.00±3.87 190.75±0.17 97.9±0.65
SD: Standard deviation
Table 3: Single factors analysis of variance (ANOVA) for % 
dissolution of marketed brands+G10
Source of variation SS df MS F p‑value
Between Groups 5191.03 8 648.88 3.698 0.002154
Within Groups 7896.96 45 175.49
Total 13087.99 53 246.94
Fig. 2: Comparative graphical presentation of % dissolution 
profile of marketed brands and formulated tablets (G10)
Fig. 3: Graphical presentation of F value
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The model dependent method, Weibull is considered as a good model in 
determination of differences among various formulations. No significant 
variations were found among all β values. The Weibull model provided 
the best adjustment curve for all the eight generic brands plus G10, with 
the higher determination coefficients R2, that is, 0.9835–0.9992. These 
curves suggested the similarity in dissolution profile of all brands along 
with formulated tablets which help to estimate the amount of drug 
dissolved as a function of time (Table 5).
Stability studies of prototype formulated tablets
After the pharmaceutical analysis of G10 tablets, they were exposed 
to stability studies [25]. Tablets were kept at accelerated stability 
conditions (40±2°C and 75±5% RH) under the three conditions such as 
Alu/Alu blister, amber, and an opened container along with refrigerator 
for comparison with standard condition. After 3 months of storage, it 
was observed that the formulated tablets (G10) were not very much 
different from innovator tablets in terms of both drug content and 
dissolution profile. No significant variation was experiential that 
evidenced the stability of formulation at accelerated conditions 
(Table 6).
CONCLUSION
The validated HPLC method was used for the evaluation of glimepiride 
tablets. The comparison of dissolution profiles concluded that the release 
of drug from the generic tablets as well as from the selected prototype 
formulated tablets was same as that of innovator tablets. Based on 
the results, it was concluded that the newly formulated glimepiride 
tablets are as good in quality as innovator. It was also concluded that 
the approach used to prepare new prototype formula was found better 
in term of rapid disintegration and maximum dissolution. The results of 
study also concluded that time to time screening of marketed products 
gave the idea about the level of the therapeutic efficacy of different 
generics of same API. Based on the finding, it was suggested, the quality 
of brand must be considered before using them as interchangeable 
medicine.
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Table 4: Similarity and difference factor (F1 and F2) among the brands+G10
Parameters G10 Glim‑B Glim‑C Glim‑D Glim‑E Glim‑F Glim‑G Glim‑H
f1 value 7.02 4.68 7.33 32.66 5.26 5.26 11.07 13.65
f2 Value 56.77 57.58 48.62 26.98 61.18 61.18 50.01 44.08
Table 5: Kinetics study of drug release for marketed and formulated tablets
Parameter Glim‑A G10 Glim‑B Glim‑C Glim‑D Glim‑E Glim‑F Glim‑G Glim‑H
Zero-order – model
k0 2.383 3.264 2.404 2.409 1.912 2.358 2.358 2.226 2.139
R2 0.4871 0.7917 0.5949 0.8097 0.8280 0.6593 0.6593 0.8258 0.8231
First-order – model
k1 0.189 0.194 0.245 0.310 0.053 0.206 0.206 0.140 0.111
R2 0.9396 0.9905 0.9981 0.9272 0.9696 0.9964 0.9964 0.9752 0.9966
Higuchi model
kH 18.928 19.366 16.994 17.046 12.752 16.602 16.602 15.499 14.841
R2 0.6486 0.8758 0.7024 0.8807 0.9051 0.7599 0.7599 0.8974 0.9001
Hixson-Crowell model
kHC 0.033 0.034 0.026 0.026 0.015 0.026 0.026 0.024 0.023
R2 0.8484 0.9815 0.8693 0.9492 0.9642 0.9074 0.9074 0.9657 0.9862
Weibull model
α 0.382 93.432 0.531 0.624 3.439 0.638 0.638 1.065 1.326
β 0.040 1.713 0.150 0.186 0.486 0.170 0.170 0.244 0.274
Ti 5.000 -9.626 4.913 3.448 4.471 4.847 4.847 4.021 3.775
R2 0.9992 0.9991 0.9892 0.9835 0.9940 0.9975 0.9975 0.9945 0.9975
Table 6: Stability study of optimized prototype formulated tablets (G10)
Test Open Blister Amber
Duration 1st Month 2nd Month 3ed Month 1st Month 2nd Month 3ed Month 1st Month 2nd Month 3ed Month
Weight 
variation (mg)
174.25±0.024 172.4±0.014 173.6±0.021 178.7±0.05 178.2±0.046 178.1±0.045 172.5±0.015 174.7±0.027 174±0.023
% Drug release 
(After 15 min)
86.26±0.45 98.48±0.37 100.13±0.44 85.85±0.50 94.77±0.49 92.07±0.62 90.85±0.61 97.09±0.41 94.42±0.62
Hardness (Kp) 2.75±0.313 2.50±0.375 2.125±0.469 3.75±0.062 3.50±0.125 3.50±0.125 3.50±0.125 3.50±0.125 3.25±0.188
Friability % 
w/w
0.33 0.11 0.37 0.22 0.19 0.21 0.36 0.34 0.41
Disintegration 
time (sec)
101±0.11 89.0±1.31 99±1.34 87±2.02 100±1.97 105±1.27 111±0.83 67±0.92 88±1.99
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